The FDA has authorized a new antibody drug, Pemgarda, to protect immunocompromised individuals from Covid-19. This drug by Invivyd is the first available since AstraZeneca’s Evusheld was pulled due to its ineffectiveness against new Omicron variants. Immunocompromised patients, including cancer and transplant recipients, eagerly anticipate this protection as their weakened immune systems may not respond adequately to vaccines. Despite over 10,000 recent Covid-19 hospitalizations, it is uncertain how many will opt for this new treatment. Invivyd plans to prioritize the 485,000 most at-risk patients initially. The company’s founder, Tillman Gerngross, designed Pemgarda to be variant-proof against Omicron.
Source link
FDA authorizes new drug to protect vulnerable from Covid-19
